当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
标题(英文)
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
条件
Gastric Adenocarcinoma
干预
Drug: Sintilimab|Drug: Ramucirumab|Drug: Cisplatin|Drug: 5-fluorouracil|Drug: Oxaliplatin|Drug: Capecitabine